{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-009233","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.476092+00:00","generated_at":"2026-05-25T22:24:58.532421+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioLife Solutions Q4 revenue $22.7M (+31% YoY); guides 2025 up 16-20%","bullets":["Q4 total revenue $22.7M (up 31% YoY); Cell Processing $20.3M (+37% YoY).","GAAP net loss from continuing ops $2.0M vs $7.2M YoY; adjusted EBITDA $4.0M (18% of revenue).","Completed sales of SciSafe and CBS in Nov 2024 for ~$79.1M total cash; cash and marketable securities $109.2M.","2025 revenue guidance $95.5-99.0M (growth 16-20%); Cell Processing $86.5-89.0M (growth 18-21%).","Cumulative 769 FDA Master File cross-references; biopreservation media in 17 approved cell/gene therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-009233","json":"https://secwatch.observer/filing/0001628280-25-009233.json","markdown":"https://secwatch.observer/filing/0001628280-25-009233.md","text":"https://secwatch.observer/filing/0001628280-25-009233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828025009233/0001628280-25-009233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828025009233/blfs-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T22:24:58.532421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}